EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Four-month real-life response to Tezepelumab in patients with multi-failure to other biologics

Diana Betancor, Sara Bautista, Raquel López-Rodríguez, Marcela Valverde-Monge, Mar Fernández-Nieto, Manuel J Rial

Allergologia et Immunopathologia · 2024

DOI: 10.15586/aei.v52i6.1161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergologia et Immunopathologia, 2024. Verfasst von Diana Betancor und 5 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the response to Tezepelumab in real clinical practice, we performed an analysis of the clinical, functional, and inflammatory characteristics of 13 patients with severe asthma after completing four doses of Tezepelumab was performed. When comparing clinical parameters such as asthma control test (ACT), FENO value, exacerbations in the last 4 months, blood eosinophils and FEV1%, before receiving Tezepelumab and after four doses of Tezepelumab, statistically significant differences were found in ACT levels (p=0.0072), exacerbations (p=0.018) and FEV1% (p=0.012) before and after four doses of Tezepelumab. No statistically significant differences were found in blood eosinophils or FeNO levels, however, a mean reduction of 102.5±231 cells/mm3 and 14.67±30 ppb, respectively, was observed. Patients with a high T2 profile had significantly higher baseline FeNO (p0.05). We demonstrated, in a multicenter study, the clinical improvement associated with tezepelumab treatment in severe uncontrolled asthma, independent of inflammatory biomarkers, eosinophilic profile, or previous biological failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsHumansMaleFemaleMiddle AgedAdultEosinophilsBiological ProductsAgedTreatment OutcomeRespiratory Function TestsNitric Oxide

Stichwörter der Autor:innen

TSLPTezepelumabbiologicsreal-world-evidencesevere asthma

Substanzen

Antibodies, Monoclonal, HumanizedAnti-Asthmatic AgentstezepelumabBiological ProductsNitric Oxide

Autor:innen und Institutionen

  • Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • CIBER Enfermedades Respiratorias, ISCIII, Madrid, Spain.
  • Allergy Department, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
  • Allergy Department, Hospital Universitario Lucus Augusti, Lugo, Spain.
  • INIBIC, A Coruña, Spain; Manuterial@gmail.com.

Zitieren

APA

Betancor, D., Bautista, S., López-Rodríguez, R., Valverde-Monge, M., Fernández-Nieto, M., & Rial, M. J. (2024). Four-month real-life response to Tezepelumab in patients with multi-failure to other biologics. Allergologia et Immunopathologia. https://doi.org/10.15586/aei.v52i6.1161

Vancouver

Betancor D, Bautista S, López-Rodríguez R, Valverde-Monge M, Fernández-Nieto M, Rial MJ. Four-month real-life response to Tezepelumab in patients with multi-failure to other biologics. Allergologia et Immunopathologia. 2024. doi:10.15586/aei.v52i6.1161

BibTeX
@article{Betancor2024,
  author = {Betancor, Diana and Bautista, Sara and López-Rodríguez, Raquel and Valverde-Monge, Marcela and Fernández-Nieto, Mar and Rial, Manuel J},
  title = {Four-month real-life response to Tezepelumab in patients with multi-failure to other biologics},
  journal = {Allergologia et Immunopathologia},
  year = {2024},
  doi = {10.15586/aei.v52i6.1161}
}
Kostenlos starten →